AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18654731
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bladder retraining and anticholinergic drugs
Trial: 16905197
Drug: Reinforcement schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcement schedule with reset in reinforcer magnitude for a positive drug test
Trial: 12546342
Drug: Clemastine (0.68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine (0.68 mg), pseudoephedrine (60 mg), and acetaminophen (1,000 mg)
Trial: 11115196
Drug: Pseudoephedrine and
RxNorm normalized name: Pseudoephedrine and terfenadine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine and acetaminophen
Trial: 8894261
Drug: Cilazapril (2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5-5 mg/day)
Trial: 6347746
Drug: Oxyphenbutazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxyphenbutazone (400 mg/day)
Trial: 23406290
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g amoxicillin one hour pre-operatively
Trial: 23406290
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules 1 hour pre-operatively
Trial: 19460761
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (anakinra 100 mg/day + pegsunercept 800 microg/kg twice a week)
Trial: 19460761
Drug: Monotherapy (anakinra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (anakinra 100 mg/day)
Trial: 16826487
Drug: Intradermal skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal skin test with heat-inactivated Lancy-Vaxina
Trial: 16826487
Drug: Positive neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive neutralizing antibody
Trial: 10890632
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg afelimomab three times daily over 3 days
Trial: 3922887
Drug: Commercial diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial diet preparation 1
Trial: 3922887
Drug: Commercial diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial diet preparation 2
Trial: 27912954
Drug: Dietary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary and lifestyle recommendations based on Iranian traditional medicine (ITM) for 3 months
Trial: 16253773
Drug: Amifostine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (200 mg/m2 i.v.) administered 15-30 min before each fraction of radiation
Trial: 28443835
Drug: 10% boric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% boric acid solution
Trial: 28443835
Drug: 5% boric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% boric acid solution at 55°C for 60s
Trial: 2427837
Drug: Celiprolol 600
RxNorm normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 600 mg
Trial: 2427859
Drug: Celiprolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (all doses)
Trial: 30146932
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (1-g capsules daily)
Trial: 17162995
Drug: 200‐mg modafinil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mg modafinil
Trial: 3723795
Drug: Blood transfusion
RxNorm normalized name: Blood transfusion, auxiliary products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood transfusion of 700 ml at a rate of 5 ml/min
Trial: 3723795
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg administered immediately before transfusion
Trial: 24608198
Drug: Intermittent oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermittent oxaliplatin (IO) administration (eight‐cycle blocks of oxaliplatin treatment)
Trial: 24608198
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and magnesium salts (Ca/Mg)
Trial: 24608198
Drug: Continuous oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous oxaliplatin (CO) administration
Trial: 19477537
Drug: G-CSF (Filgrastim)
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (Filgrastim) at a dose of 10 μg/kg body weight/day subcutaneously
Trial: 19477537
Drug: G-CSF and
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF and Placebo
Trial: 23278517
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (locator)
Trial: 22348650
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control condition (online supportive therapy)
Trial: 18516353
Drug: Calcium lactate
RxNorm normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate supplementation (170 mg of calcium lactate and 60 mg of vitamin C, one tablet three times a day for four weeks)
Trial: 14616171
Drug: MKC-733 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MKC-733 (4 mg)
Trial: 10539777
Drug: Antioxidant mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant mixture (440 alpha‐TE, 2000 RE of beta‐carotene, 500 mg ascorbic acid, 100 microg selenium, 30 mg zinc daily)
Trial: 10539777
Drug: Single antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antioxidant supplements (Vitamin E, Vitamin A, Vitamin C)
Trial: 8644907
Drug: Special vessels
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special vessels and chlorine (5% calcium hypochlorite solution)
Trial: 1751573
Drug: Control measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control measurement (1 week before treatment)
Trial: 6805119
Drug: Complete parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete parenteral nutrition for 2 days preoperatively and 6 days postoperatively
Trial: 6805119
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no parenteral nutrition)
Trial: 17375114
Drug: Complete parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete parenteral nutrition
Trial: 28949260
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg CoQ10 per day for 12 weeks
Trial: 8249842
Drug: piretanide 6
RxNorm normalized name: piretanide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piretanide 6 mg + ramipril 5 mg
Trial: 8249842
Drug: piretanide 3
RxNorm normalized name: piretanide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piretanide 3 mg
Trial: 8249842
Drug: piretanide 6
RxNorm normalized name: piretanide 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piretanide 6 mg
Trial: 8249842
Drug: ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 2.5 mg
Trial: 8249842
Drug: ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 10 mg
Trial: 2938471
Drug: Flurbiprofen 150
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 150 mg per day for 6 days
Trial: 2938471
Drug: Flurbiprofen 200
RxNorm normalized name: flurbiprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 200 mg per day for 3 weeks
Trial: 2938471
Drug: Flurbiprofen 400
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 400 mg per day for 7 days
Trial: 18493882
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (n=28)
Trial: 18493882
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (n=32)
Trial: 12593522
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 3,200 microg day(‐1) b.i.d.
Trial: 12593522
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 1,600 microg day(‐1) b.i.d.
Trial: 12593522
Drug: Beclometasone dipropionate
RxNorm normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beclometasone dipropionate (BDP) 800 microg day(‐1) b.i.d. via metered-dose inhaler (MDI) plus spacer
Trial: 9445198
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (18 g of omega-3 polyunsaturated fatty acids, PUFA)
Trial: 7632640
Drug: Estraderm TTS
RxNorm normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estraderm TTS 100 micrograms twice weekly
Trial: 7632640
Drug: Estraderm TTS
RxNorm normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estraderm TTS 200 micrograms twice weekly
Trial: 319816
Drug: Fentanyl 0.05
RxNorm normalized name: fentanyl 0.05 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.05 mg
Trial: 24252064
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments in the hospital (Control group)
Trial: 20369558
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of improved sex therapy and oral sildenafil for 3 months
Trial: 20369558
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil alone for 3 months
Trial: 12456446
Drug: Gabapentin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (15 mg/kg/day in 3 divided doses)
Trial: 10546710
Drug: Outpatient therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient therapy with two 1-g doses of intramuscular ceftriaxone at 24-hour intervals followed by oral cephalexin
Trial: 10546710
Drug: Inpatient therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient therapy with two 1-g doses of intramuscular ceftriaxone at 24-hour intervals followed by oral cephalexin
Trial: 10546710
Drug: Outpatient therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient therapy
Trial: 7573232
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of thyrotropin‐releasing hormone
Trial: 7573232
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms of thyrotropin‐releasing hormone
Trial: 2347114
Drug: 1% ciclopiroxolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ciclopiroxolamine solution applied once daily for 1, 2, or 3 days
Trial: 6670732
Drug: Fentanyl (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.1 mg) and Atropine (0.01 mg/kg b.w.)
Trial: 6670732
Drug: Innovar (Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovar (Fentanyl (0.1 mg) and Droperidol (5 mg))
Trial: 6670732
Drug: Innovar (Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovar (Fentanyl (0.1 mg) and Droperidol (5 mg)) plus Atropine (0.01 mg/kg b.w.)
Trial: 27510595
Drug: BAI 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAI 320 μg/day
Trial: 27510595
Drug: BAI 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAI 640 μg/day
Trial: 27510595
Drug: MDI 640
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI 640 μg/day
Trial: 24702835
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg per day) plus folic acid
Trial: 24702835
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg per day) plus folic acid in original stratum
Trial: 24702835
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (81 mg per day) plus folic acid in expanded stratum
Trial: 15848537
Drug: Daclizumab induction
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab induction (2 mg/kg) on PTD 0 and 14
Trial: 15848537
Drug: Thymoglobulin induction
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin induction (1.5 mg/kg) on PTD 0 and 2 followed by daclizumab on POD 14
Trial: 12222700
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg/day) therapy adjunctive to thrombolytic therapy
Trial: 7714788
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine (0, 37.5, 75, 150 or 300 mg/70 kg)
Trial: 2667749
Drug: Metoclopramide (M)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (M) at 4 mg/kg combined with dexamethasone (D) at 40 mg
Trial: 2667749
Drug: Metoclopramide (M)
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide (M) at 1, 2, and 4 mg/kg total dose
Trial: 840119
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with 3 weeks of bed rest for patients not suitable for early mobilisation
Trial: 1568631
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g i.v. cefotaxime
Trial: 1568631
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g amoxicillin plus clavulanic acid
Trial: 4068610
Drug: Antacid (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (group A)
Trial: 4068610
Drug: H2 blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: H2 blocker (group B)
Trial: 4068610
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (group A and B)
Trial: 24387078
Drug: Tadalafil 5
RxNorm normalized name: tadalafil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 5 mg once daily combined with sildenafil 50 mg as needed
Trial: 16569261
Drug: Cefepime with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime with levofloxacin (C-L group, 20 patients)
Trial: 16569261
Drug: Cefepime with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime with levofloxacin (C-L group)
Trial: 3919604
Drug: Disodium Cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium Cromoglycate (DSCG) (5.2 mg 5 times daily)
Trial: 29961573
Drug: Tocilizumab (IL-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (IL-6 receptor antagonist)
Trial: 29374714
Drug: Thoracic radiotherapy
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiotherapy (TRT) of 45 Gy/30 fractions (twice daily)
Trial: 29374714
Drug: Thoracic radiotherapy
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiotherapy (TRT) of 42 Gy/15 fractions (once daily)
Trial: 23949963
Drug: Umeclidinium 62.5
RxNorm normalized name: UMECLIDINIUM 62.5MCG 7D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium 62.5 μg
Trial: 18797405
Drug: TMZ+training (TT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMZ+training (TT), n=30, received TMZ 20 mg three times daily for 8 weeks and underwent exercise training at 60% of oxygen uptake at peak, three times a week for 8 weeks.
Trial: 18797405
Drug: TMZ (n=30),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMZ (n=30), received TMZ 20 mg three times daily for 8 weeks without exercise training.
Trial: 8430276
Drug: Duodenal perfusion
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal perfusion with pancreaticobiliary juice at a rate of 5 ml/min for 10 min
Trial: 8430276
Drug: Saline at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline at a rate of 5 ml/min for 10 min
Trial: 31997509
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg Livergol capsule per day for 30 days
Trial: 31997509
Drug: Starch-containing capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch-containing capsule as a placebo once a day for 30 days
Trial: 27819257
Drug: Preemptive antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Trial: 27819257
Drug: Empirical antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antifungal therapy with voriconazole (initiating dose of 400 mg, then reduced to 200 mg every 12 hours)
Trial: 24304990
Drug: Insulin (group-A)
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (group-A)
Trial: 24304990
Drug: Metformin (group-B)
RxNorm normalized name: meningococcal group B vaccine
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (group-B)
Trial: 19484982
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) by nasal spray
Trial: 19484982
Drug: Nasal spray-inhaling
RxNorm normalized name: Allerest 12 Hour Nasal Spray Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray-inhaling combined administration
Trial: 16887471
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole 1500 mg day(‐1)
Trial: 16887471
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole 1000 mg day(‐1)
Trial: 16887471
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole 500 mg every 8 h
Trial: 15646945
Drug: Manual brushing
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual brushing and daily flossing
Trial: 11298072
Drug: Clinical pharmacy
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical pharmacy intervention involving development of professional relationships, nurse education on medication issues, and individualized medication reviews
Trial: 2547139
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg piperazine oestrone sulphate/day
Trial: 2547139
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg piperazine oestrone sulphate + 5.0 mg oestriol/day
Trial: 2547139
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg oestradiol valerate/day
Trial: 2547139
Drug: 10.0 mg
RxNorm normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mg oestriol/day
Trial: 2547139
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with levonorgestrel (LNG) 250 micrograms/day
Trial: 14651947
Drug: Capsaicin injection
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsaicin injection
Trial: 19084439
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide 0.33 microg kg(‐1)h(‐1) infusion
Trial: 12548313
Drug: Polyunsaturated spread
RxNorm normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated spread with 2 g of plant sterols
Trial: 8296077
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg/day (n = 27)